J&J’s second Halda asset goes clinical
An anti-ER “Riptac” enters phase 1.
Roche sounds another warning over co-stimulation
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
ASCO 2026 preview – recent wins come under the spotlight
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Toxicity doesn't stop Incyte
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
ASCO 2026 preview – Revolution completes its rout
Daraxonrasib scores a plenary session late-breaker.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
Ominous signs for EGFR degraders
BeOne's degrader BG-60366 appears to have been discontinued.
